Veverimer for Metabolic Acidosis

This trial tests the effectiveness and safety of a new treatment called veverimer for individuals with moderate-to-severe chronic kidney disease (CKD) who also have metabolic acidosis, a condition characterized by excess acid in the body. The trial compares veverimer with a placebo to determine its impact on the condition. It suits adults managing CKD and metabolic acidosis who do not anticipate major changes, such as starting dialysis soon. Participants must maintain a stable diet and medication routine. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment.

You may need to stop or adjust some of your current medications before joining the trial. Specifically, you should not start or change the dose of certain medications like diuretics, diabetes drugs, and others listed in the trial criteria, within 28 days before the trial and during the study.

Research has shown that veverimer is generally safe for people with metabolic acidosis, a condition where there is too much acid in the body related to chronic kidney disease (CKD). Studies indicate that veverimer effectively corrects this acid imbalance. Serious side effects occurred in only 2% of patients taking veverimer, compared to 5% in the placebo group, suggesting that veverimer is well-tolerated. Additionally, it does not add extra sodium or potassium to the body, which enhances its safety profile. Overall, veverimer appears to be a promising and safe treatment option for those with CKD and metabolic acidosis.¹²³⁴⁵

Veverimer is unique because it targets metabolic acidosis by binding to and removing acid from the gastrointestinal tract, which is different from current treatments that often focus on managing symptoms with alkaline substances like sodium bicarbonate. Unlike the standard of care, Veverimer acts directly on the underlying cause of metabolic acidosis, offering a potentially more direct and effective approach. Researchers are excited about Veverimer because it offers a new mechanism of action and might provide a more targeted and efficient treatment option for patients with metabolic acidosis.

Studies have shown that veverimer effectively treats metabolic acidosis in people with chronic kidney disease (CKD). Research indicates that veverimer raises bicarbonate levels in the blood, which is crucial for maintaining acid balance. In some studies, up to 63% of patients taking veverimer experienced significant improvement in their bicarbonate levels. Additionally, patients reported feeling better physically after taking veverimer. These findings suggest that veverimer can help manage metabolic acidosis in CKD. Participants in this trial will receive either veverimer or a placebo to further evaluate its effectiveness.²⁴⁵⁶⁷